MARKER THERAPEUTICS (MRKR)
(Delayed Data from NSDQ)
$3.64 USD
-0.39 (-9.68%)
Updated Jun 4, 2024 03:59 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Balance Sheet
Fiscal Year End for MARKER THERAPEUTICS, INC falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 15 | 12 | 44 | 21 | 44 |
Receivables | 1 | 2 | 0 | 1 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 1 | 2 | 2 | 2 | 2 |
Total Current Assets | 17 | 17 | 46 | 24 | 45 |
Net Property & Equipment | 0 | 12 | 12 | 10 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 17 | 34 | 68 | 46 | 46 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 2 | 5 | 11 | 6 | 2 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 1 | 3 | 1 | 0 | 0 |
Total Current Liabilities | 3 | 8 | 13 | 6 | 2 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 3 | 15 | 24 | 18 | 2 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 450 | 448 | 442 | 384 | 372 |
Retained Earnings | -436 | -428 | -398 | -356 | -328 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 14 | 20 | 44 | 27 | 44 |
Total Liabilities & Shareholder's Equity | 17 | 34 | 68 | 46 | 46 |
Total Common Equity | 14 | 20 | 44 | 27 | 44 |
Shares Outstanding | 8.80 | 8.30 | 8.30 | 5.00 | 4.50 |
Book Value Per Share | 1.60 | 2.36 | 5.30 | 5.47 | 9.80 |
Fiscal Year End for MARKER THERAPEUTICS, INC falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 11 | 15 | 17 | -99,981 | 6 |
Receivables | 2 | 1 | 0 | 2 | 2 |
Notes Receivable | 0 | 0 | 0 | NA | 0 |
Inventories | 0 | 0 | 0 | NA | 0 |
Other Current Assets | 1 | 1 | 2 | 2 | 2 |
Total Current Assets | 14 | 17 | 19 | 22 | 11 |
Net Property & Equipment | 0 | 0 | 0 | NA | 12 |
Investments & Advances | 0 | 0 | 0 | NA | 0 |
Other Non-Current Assets | 0 | 0 | 0 | NA | 0 |
Deferred Charges | 0 | 0 | 0 | NA | 0 |
Intangibles | 0 | 0 | 0 | NA | 0 |
Deposits & Other Assets | 0 | 0 | 0 | NA | 0 |
Total Assets | 14 | 17 | 19 | 22 | 28 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | NA | 0 |
Accounts Payable | 2 | 2 | 2 | 3 | 5 |
Current Portion Long-Term Debt | 0 | 0 | 0 | NA | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | NA | 0 |
Accrued Expenses | 0 | 0 | 0 | NA | 0 |
Income Taxes Payable | 0 | 0 | 0 | NA | 0 |
Other Current Liabilities | 0 | 1 | 0 | 0 | 0 |
Total Current Liabilities | 2 | 3 | 3 | 3 | 5 |
Mortgages | 0 | 0 | 0 | NA | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | NA | 0 |
Convertible Debt | 0 | 0 | 0 | NA | 0 |
Long-Term Debt | 0 | 0 | 0 | NA | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | NA | 0 |
Other Non-Current Liabilities | 0 | 0 | NA | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | NA | 0 |
Total Liabilities | 2 | 3 | 3 | 3 | 12 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | NA | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 450 | 450 | 450 | 450 | 449 |
Retained Earnings | -439 | -436 | -433 | -431 | -433 |
Other Equity | 0 | 0 | 0 | NA | 0 |
Treasury Stock | 0 | 0 | 0 | NA | 0 |
Total Shareholder's Equity | 12 | 14 | 17 | 19 | 16 |
Total Liabilities & Shareholder's Equity | 14 | 17 | 19 | 22 | 28 |
Total Common Equity | 12 | 14 | 17 | 100,018 | 16 |
Shares Outstanding | 8.90 | 8.80 | 8.80 | 8.80 | 8.80 |
Book Value Per Share | 1.32 | 1.60 | 1.90 | 11,365.69 | 1.81 |